[go: up one dir, main page]

MX2013014071A - Combinacion de tratamiento de sinergia para el tratamiento del carcinoma de celula escamosa de cabeza y cuello. - Google Patents

Combinacion de tratamiento de sinergia para el tratamiento del carcinoma de celula escamosa de cabeza y cuello.

Info

Publication number
MX2013014071A
MX2013014071A MX2013014071A MX2013014071A MX2013014071A MX 2013014071 A MX2013014071 A MX 2013014071A MX 2013014071 A MX2013014071 A MX 2013014071A MX 2013014071 A MX2013014071 A MX 2013014071A MX 2013014071 A MX2013014071 A MX 2013014071A
Authority
MX
Mexico
Prior art keywords
treatment
cell carcinoma
squamous cell
neck
head
Prior art date
Application number
MX2013014071A
Other languages
English (en)
Other versions
MX358501B (es
Inventor
Veena Agarwal
Arun Balakrishnan
Giridharan Periyasamy
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd filed Critical Piramal Entpr Ltd
Publication of MX2013014071A publication Critical patent/MX2013014071A/es
Publication of MX358501B publication Critical patent/MX358501B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con una combinación farmacéutica para uso en el tratamiento contra el carcinoma de célula escamosa, comprende un inhibidor CDK seleccionado de los compuestos de la fórmula (I) o una sal farmacéuticamente aceptable del mismo y uno o más agentes antineoplásticos seleccionados de sorafenib, lapatinib, erlotinib, Cisplatinaa, 5-fluorouracel, docetael o cetuximab o una sal farmacéuticamente aceptable del mismo. La combinación farmacéutica presenta sinergia cuando cuando se utiliza en el tratamiento del carcinoma de célula escamosa. Esta invención se relaciona con una composición farmacéutica que comprende tal combinación y un método para el tratamiento del carcinoma de célula escamosa de cabeza y cuello (SCCHN), utilizando una cantidad terapéuticamente efectiva del tal combinación.
MX2013014071A 2011-05-31 2012-05-30 Combinación farmacéutica de sinergia para el tratamiento del carcinoma de célula escamosa de cabeza y cuello. MX358501B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161491569P 2011-05-31 2011-05-31
PCT/IB2012/052698 WO2012164497A1 (en) 2011-05-31 2012-05-30 A synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck

Publications (2)

Publication Number Publication Date
MX2013014071A true MX2013014071A (es) 2014-05-28
MX358501B MX358501B (es) 2018-08-23

Family

ID=46551791

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014071A MX358501B (es) 2011-05-31 2012-05-30 Combinación farmacéutica de sinergia para el tratamiento del carcinoma de célula escamosa de cabeza y cuello.

Country Status (16)

Country Link
US (4) US20140112918A1 (es)
EP (1) EP2714031B1 (es)
JP (1) JP2014515394A (es)
KR (1) KR20140056190A (es)
CN (1) CN103561734B (es)
AR (1) AR086625A1 (es)
AU (1) AU2012264246A1 (es)
BR (1) BR112013030820A2 (es)
CA (1) CA2837042C (es)
DK (1) DK2714031T3 (es)
ES (1) ES2682270T3 (es)
IL (1) IL229601A0 (es)
MX (1) MX358501B (es)
RU (1) RU2013158914A (es)
TW (1) TW201300105A (es)
WO (1) WO2012164497A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
AR096892A1 (es) 2013-07-12 2016-02-03 Piramal Entpr Ltd Una combinación farmacéutica para el tratamiento del melanoma
WO2015181737A1 (en) 2014-05-28 2015-12-03 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
US11135198B2 (en) 2016-03-28 2021-10-05 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
SG11202008669YA (en) * 2018-03-13 2020-10-29 Innate Pharma Treatment of head and neck cancer
RU2711308C1 (ru) * 2019-07-13 2020-01-16 Михаил Сергеевич Ольшанский Способ паллиативного лечения рецидивов плоскоклеточного рака головы и шеи
US20240293413A1 (en) * 2021-06-10 2024-09-05 Onquality Pharmaceuticals China Ltd. Compound and method for treating chemotherapy-related gastrointestinal side effects

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (es) 1986-04-11 1989-02-04 Hoechst India
USH1427H (en) 1988-04-06 1995-04-04 Briet; Phillipe Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2
US5116954A (en) 1988-04-06 1992-05-26 Lipha, Lyonnaise Industrielle Pharmaceutique Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5723313A (en) 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
CA2401748A1 (en) 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
KR20030017569A (ko) 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
US7915301B2 (en) 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
US7271193B2 (en) 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
TWI331034B (en) * 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7884127B2 (en) * 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
WO2004041308A1 (en) 2002-11-06 2004-05-21 Cyclacel Limited Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
GB0328180D0 (en) 2003-12-04 2004-01-07 Cyclacel Ltd Combination
CA2548491A1 (en) 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
EP1856083A4 (en) 2005-03-11 2009-05-27 Univ Michigan CHROMENE-4-ON-INHIBITORS OF ANTI-APOPTOTIC MEMBERS OF THE BCL-2 FAMILY AND THEIR USES
US8563596B2 (en) * 2006-06-21 2013-10-22 Piramal Enterprises Limited Enantiomerically pure compounds for the treatment of proliferative disorders
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
US8822526B2 (en) * 2007-05-15 2014-09-02 Piramal Enterprises Limited Synergistic pharmaceutical combination for the treatment of cancer
WO2009014642A1 (en) * 2007-07-19 2009-01-29 Amgen Inc. Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer
TWI461194B (zh) 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
EP2502078A1 (en) * 2009-11-20 2012-09-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物

Also Published As

Publication number Publication date
CN103561734A (zh) 2014-02-05
AU2012264246A1 (en) 2014-01-09
US10245251B2 (en) 2019-04-02
US20190167639A1 (en) 2019-06-06
DK2714031T3 (en) 2018-08-06
EP2714031B1 (en) 2018-05-23
US20140112918A1 (en) 2014-04-24
CN103561734B (zh) 2017-07-11
ES2682270T3 (es) 2018-09-19
JP2014515394A (ja) 2014-06-30
US10980776B2 (en) 2021-04-20
EP2714031A1 (en) 2014-04-09
RU2013158914A (ru) 2015-07-10
IL229601A0 (en) 2014-01-30
CA2837042A1 (en) 2012-12-06
MX358501B (es) 2018-08-23
US20210196680A1 (en) 2021-07-01
NZ619488A (en) 2015-09-25
AR086625A1 (es) 2014-01-08
KR20140056190A (ko) 2014-05-09
CA2837042C (en) 2018-12-11
US20170157090A1 (en) 2017-06-08
BR112013030820A2 (pt) 2016-12-06
WO2012164497A1 (en) 2012-12-06
TW201300105A (zh) 2013-01-01

Similar Documents

Publication Publication Date Title
MX2013014071A (es) Combinacion de tratamiento de sinergia para el tratamiento del carcinoma de celula escamosa de cabeza y cuello.
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
HK1201828A1 (en) Treatment regimens using multiple pharmaceutical agents
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX369385B (es) Productos para cicatrizar heridas tisulares.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
TW201613887A (en) Antiproliferative compounds and methods of use thereof
PH12014500386A1 (en) Combination treatment for hepatitis c
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
MX2013012588A (es) Inhibidores de cinasa.
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
PH12016502353A1 (en) Pharmaceutical composition
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
BR112014010729A2 (pt) métodos para tratamento de ataques de gota
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
WO2012161497A3 (ko) 보습능이 우수한 펩타이드 유도체 및 이의 용도

Legal Events

Date Code Title Description
FG Grant or registration